ABSTRACT. Total lipids, lipoprotein-lipids, and apolipo-VLDL-C, cholesterol in the VLDL fraction proteins were studied in plasma of 20 patients, aged 13.9
patients treated with continuous peritoneal dialysis have tein fractions and plasma apolipoprotein levels in children atherogenic lipoprotein profiles, cholesterol ratios, and treated with CAPD/CCPD have not been well defined. Moreapolipoprotein ratios, but normal cholesterol in the high over, it is unknown whether continuous losses of apolipoproteins density fraction and apo A-I levels despite considerable in the dialysate (6) could significantly affect plasma apo A-I losses in the dialysate. (Pediatr Res 29: 155-159, (apo)lipoprotein-levels in.these patients. Because peritoneal mass
1991)
transfer is size-dependent, losses of apo A-I (apparent mol wt 28 000 D) are likely to exceed the losses of apo B by far (apparent mol wt 550 000 D). It is thus possible that the already disturbed Abbreviations lipoprotein profile of uremic patients could be further aggravated by peritoneal dialysis. This would constitute a serious disadvan-C, total plasma cholesterol tage of treatment with CAPDICCPD, considering the physiologic CAPD, continuous ambulatory peritoneal dialysis importance of HDL (3). Furthermore, it has not been evaluated CCPD, continuous cycling peritoneal dialysis whether lipoprotein profiles are influenced by nutritional status HDL-C, cholesterol in the HDL fraction and/or obesity in children treated with CAPDICCPD. Indices of LDL-C, cholesterol in the LDL fraction obesity are correlated with serum lipid levels in normal children TG, total plasma triglycerides and adolescents (7) and obesity has been reported as an inde- tients.
156
QUERFELD ET AL.
MATERIALS AND METHODS
Twenty patients were studied, 10 male and 10 female, aged 13.9 + 3.4 (range 7.4 to 19) y, who were treated with CAPD/ CCPD for a period of 2.1 + 1.2 (0.5 to 4.9) y. All were nonnephrotic, free of peritonitis for at least 4 wk before the study, and not receiving any drugs (including antihypertensive and immunosuppressive medication) affecting lipid metabolism. End stage renal disease was due to the following diseases: Alport syndrome (n = 4), renal dysplasia (n = 6), focal segmental glomerulosclerosis (n = 4), membrano-proliferative glomerulonephritis (n = I), rapid progressive glomerulonephritis (n = 2), polycystic kidney disease (n = 2), and Wilms tumor (n = I). The control group consisted of 17 pediatric patients, 10 male and seven female, aged 13.0 f 5.1 (range 5.1 to 19) y, who were hospitalized for minor surgical procedures and were free of chronic illness. Hyperlipidemia was defined as a plasma lipid level above the 95th percentile for TG (1 12 mg/dL) or C (197 mg/dL) levels in control subjects. In addition, lipid levels of each patient were compared with the 95th percentile or 5th percentile of lipid levels in normal children matched for age and sex, as published by the Lipid Research Clinics (9) . Among patients and controls, no differences were found between male and female participants in this study, so data were pooled for analysis.
A dietician measured the patient's height and weight, as previously described (10) . The ideal body weight was calculated as the weight corresponding to the 50th percentile for height age of normal children (1 1). Nutritional status was assessed by calculation of the percentage of ideal body weight and percentages of "ideal" mid-arm circumference, mid-arm muscle circumference, and triceps skinfold thickness, which were defined as the 50th percentile of values in normal children (12) of the patient's height age.
The study protocol was approved by the institutional human subject protection committee and informed consent was obtained from all patients and control subjects and/or their parents before study.
Lipid determination. After an overnight fast of at least 10 h, blood was drawn into Na-EDTA tubes and immediately analyzed for total plasma lipids and lipoprotein lipids. TG and C and lipid levels in lipoprotein fractions were determined by enzymatic methods using a centrifugal autoanalyzer. VLDL were isolated by ultracentrifugation at a density < 1.006 g/mL (1 3). HDL were obtained from the density > 1.006 g/mL fraction after precipitation of LDL with phosphotungstate/Mgf+ (14) . LDL-C was calculated as the difference between C and the sum of VLDL-C and HDL-C values.
Apolipoprotein quantitation in plasma. Aliquots of 1 mL plasma were stored at 4°C and concentrations of apo A-I and apo B were measured within 2 wk. The levels of plasma apo A-I and apo B were determined by radial immunodiffusion (15) using commercially available kits (Tago, Burlingame, CA and Boehringer, Mannheim, FRG, respectively). The interassay variation was 10 and 12%, respectively, for the apo A-I and apo B assays; intraassay variation was 5% with both methods.
Apolipoprotein quantitation in dialysate. The dialysate eMuent from 10 patients, aged 15.6 + 4.0 (range 10 to 20.7) y, was collected in sterile bags for analysis of total protein and apolipoprotein content. The total 24-h dialysate outflow volume was measured and aliquots were stored at 4°C with the addition of 0.02% (final concentration) NaN3, 0.04% NaEDTA, and 0.005% gentamicin and analyzed within 2 wk. An aliquot (50 mL) was adjusted to a solution density of 1.21 g/mL by dialysis against concentrated NaBr and subjected to ultracentrifugation (48 h, 45 000 rpm, SW 41 rotor) to obtain a total lipoprotein fraction, called the "top" fraction, and a lipoprotein-free fraction, called the "bottom" fraction. Both the top and bottom fractions were desalted by centrifugation through G-25 Sepharose spin columns before quantification of apolipoproteins.
Quantitative immunoblotting was used to determine apo A-I concentrations in dialysate fractions. Thirty to 100 pL of dialysate were applied to SDS 12% polyacrylamide gels and proteins were separated by electrophoresis (16) . The proteins were then electrophoretically transferred to nitrocellulose filters (0.2 pm pore size; Sartorius Filters, Inc., Hayward, CA) at 150 mA for 15-20 h (17) . Apo A-I was detected after incubation of filters with monospecific antiserum (diluted 1: 1000) followed by incubation with iodinated protein A. Antiserum for apo A-I was a generous gift from Dr. Steve Kunitake (University of California at San Francisco) and was prepared in rabbit to isolate human apo A-I. Protein bands were visualized by autoradiography and quantitated by excision and gamma-counting of the appropriate areas of the filters. Absolute concentrations of apolipoproteins were determined by comparison with standard curves of isolated apolipoproteins. Interassay variation was 12% and the sensitivity of the method was < 1 pg of apo A-I/mL of dialysate concentrate.
All samples were run in duplicate and intraassay variation was 2%. A RIA was used to determine apo B in dialysate top and bottom fractions, using an affinity-purified rabbit antibody against human apo B as a probe (18) . Total protein in dialysate was determined by precipitation with 10% trichloroacetic acid (19) . The average recovery with this method was 85 f 16%.
Statistical analysis was performed using least squares linear regression, multivariate regression, the Mann-Whitney U test, and the Spearman rank correlation coefficient.
RESULTS
Plasma lipoproteins. Triglyceride and cholesterol concentrations in plasma and in the VLDL, LDL, and HDL fractions, as well as plasma apolipoprotein levels of the patients, are shown in Table 1 . Compared with control values (Fig. I) , TG, VLDL-TG, C, VLDL-C, and LDL-C levels were increased, whereas HDL-C levels were not different. The lipid levels in the VLDL and LDL fractions were correlated with the respective total lipid levels (TG, C) in plasma. In addition, TG and VLDL-TG were positively correlated with VLDL-C (r = 0.78) and LDLC (r = 0.5; p < 0.05), and negatively correlated with HDL-C (r = -0.55; p < 0.05) levels. Both the C/HDL-C (5.5 + 2.6 versus 3.7 + 1.2; p < 0.01) and the LDL-C/HDL-C (3.9 f 2.1 versus 2.5 + 1.1; p < 0.05) ratios were increased in the patients compared with control values. Compared with the control group, hypertriglyceridemia was present in 17 (85%) of the patients, and six of these additionally had hypercholesterolemia; thus, 30% of the patients had combined hyperlipidemia. Compared with published normal values for children (9), 13 patients (65%) were hypertriglyceridemic and six (30%) had hypercholesterolemia. Figure 2 shows the distribution of lipoprotein lipid levels in our patients around the 95th and 5th percentile (for HDL), respectively, of published normal values.
Apo A-I plasma levels in the patients were similar to those of controls (1 12 + 26 versus 115 + 26 mg/dL) and were positively correlated with HDL-C levels (r = 0.83). Apo B plasma levels in the patients were higher than in controls (86 + 27 versus 66 + 18 mg/dL; p < 0.0 1) and were correlated with C (r = 0.5 1) and LDL-C levels (r = 0.59). The apo A-I/apo B ratio was decreased in patients (1.4 f 0.6 versus 1.9 f 0.7; p < 0.05), whereas the difference in the apo A-I/HDL-C ratio was not significant (3.2 f 1.2 versus 2.9 f 0.6 in controls). Sex, patient age, duration of treatment with CAPD/CCPD, and diagnoses of underlying renal diseases were not correlated with other measurements. Apolipoproteins in dialysate effluent. Apo A-I (Fig. 3) and apo B were found in the dialysate of all patients studied ( Table 2 ).
The daily loss of total protein was 2.5 + 1.6 g, or 76.7 f 31.1 mg/kg. The daily losses of apo A-I and apo B were not correlated with each other or their respective plasma levels. However, apo A-I losses (per kg), but not apo B or total protein losses, were correlated with TG (r = 0.85), VLDL-TG (r = 0.76), and VLDL-C (r = 0.86) levels in plasma. Losses of apolipoproteins and total protein were not correlated with age or duration of dialysis treatment.
Nutritional status. The average nutritional status of the patients, assessed as percentage of ideal body weight, was close to 100% of ideal values (106 k 16%). Similar results were found for the calculated percentages of ideal mid-arm circumference (99 + 13%), mid-arm muscle circumference (104 + lo%), and triceps skinfold thickness (89 + 47%). None of these anthropometric measurements correlated with either the lipid levels or the apolipoprotein levels.
DISCUSSION
Our study demonstrates the presence of a highly abnormal lipoprotein profile in pediatric patients treated with CAPD/ CCPD, whether compared with a control group of similar age or with sex-and age-matched published normal values. A similar lipoprotein profile has been described in adult patients treated with CAPD (20-25), although in most studies HDL-C levels were found to be decreased, except in normotriglyceridemic patients (6, 24) . Our patients had normal HDL-C levels, but significant increases in total plasma lipid levels and VLDL-TG, VLDL-C, and LDL-C levels. Because cholesterol in the LDL fraction was not directly measured but calculated, it cannot be concluded from these data whether the elevated LDL-C levels in our patients were confined to LDL or whether they also included cholesterol levels in the intermediate density lipoprotein fraction. Increases in intermediate density lipoproteins, indicating defective VLDL catabolism and a high atherogenic potential, have been reported in adult patients on maintenance hemodialysis treatment (26, 27) .
In our study, the C/HDL-C ratio was increased by 49% compared with controls. With an average chronologic age of 13 y, our patients had a C/HDLC ratio of 5.5, clearly above the 95th percentile of normal values for this age group (2.2) reported by the Lipid Research Clinics (28) . Moreover, this ratio exceeds that of 50-to 79-y-old men (5.0) with an "average risk" for myocardial infarction who participated in the Framingham Study (29) . Similarly, the LDL-C/HDL-C ratio was increased by 56%, which may be of particular significance for young patients. A recent study comparing data for 105 survivors of myocardial infarction under age 45 with age-matched healthy controls found that only the LDL/HDL-C ratio and apo B levels were strongly correlated with the severity of the disease (30) .
Several studies in adults have indicated that plasma apolipoprotein levels may be better predictors of atherosclerosis than lipoprotein lipid levels (31) (32) (33) . In children, apo A-I and apo B and their ratio, but not serum lipids or lipoprotein lipid levels, were found to be correlated with parental myocardial infarction (34). Our patients had normal apo A-I, but elevated apo B plasma levels, resulting in a decrease of the apo A-I/apo B ratio by 26% compared with controls. Studies in adult patients treated with CAPD/CCPD have found normal (22, 35) or decreased (36) apo A-I and increased apo B levels (22, 36, 37) .
The presence of lipoproteins and apolipoproteins in the dialysate has been reported in previous studies (6, (38) (39) (40) . Daily HDL-C losses ranged from 10 to 15 mg (38) in four pediatric patients, and (calculated from the data) from 26 to 65 mg in four adult patients (6) . In the latter study, it was concluded that lipoprotein losses were small and that free apolipoprotein losses were minimal. In contrast, HDL losses of approximately one third of the daily synthesis rate and an inverse relationship between plasma levels and the peritoneal clearance of HDL could be demonstrated in a recent study (39) .
Two other studies have estimated apolipoprotein losses in the dialysate. In five adult CAPD patients, significant apo A-I losses (52-1 32 mg/d) and negligible apo B losses were detected with an electroimmunoassay method (37) . Measured by single radial immunodiffusion, daily apo A-I and apo B losses were 83.7 k 15.1 and 38.9 k 12.1 mg, respectively, in another group of five adult CAPD patients (40) . With a more sensitive technique, our study demonstrates considerably higher apo A-I losses, mainly due to high concentrations of free apo A-I in the dialysate. Peritoneal mass transfer of free plasma apo A-I, which normally constitutes 10% of the total plasma pool (41), but can be found in increased concentrations in patients with chronic renal failure (42) , may account for the high amounts of free apo A-I in the dialysate. Another explanation might be dissociation of the apoprotein from HDL in the dialysate, inasmuch as reversible dissociation from lipoproteins is characteristic of apo A-I in plasma (43) . Daily losses of apo A-I and apo B were comparable to those reported for other proteins of similar size (44, 45) and marked differences in dialysate losses between individuals were obvious, as noted by other investigators (44) . Both proteins were present in the dialysate of all patients studied and apo A-I losses were much higher than losses of apo B. At nearly equal plasma levels of these proteins, this finding is most likely due to size-dependent peritoneal mass transfer (44, 45) , which clearly favors apo A-I. However, preferential HDL and apo A-I losses apparently did not have a profound effect on the lipoprotein profile of these patients, inasmuch as HDL-C and apo A-I plasma levels were normal.
The average nutritional status of our patients was close to ideal, i.e. comparable to normal children of the same height age. Plasma lipid and lipoprotein lipid levels were not correlated with indices of body fat deposition or muscle mass. Therefore, anthropometric measurements in children treated with CAPD/ CCPD do not seem to be correlated with cardiovascular risk as assessed by lipoprotein profiles. In summary, our study demonstrates an "atherogenic" lipoprotein profile in children treated with CAPD/CCPD: high total plasma lipids (TG and C), high C/HDL-C and LDL-C/HDL-C ratios and an abnormal apolipoprotein composition with a low apo A-I/B ratio. Preliminary data from autopsies of children who underwent hemodialysis were suggestive of early atherosclerotic changes (46) ; however, it is yet unknown whether these lipid abnormalities will invariably lead to an accelerated course of atherosclerosis (47) .
